Dr Paul Marshall has joined the Nerudia team as a regulatory principal. His role will be to support customers with medicinal, PMTA and TPD projects. As a former senior pharmaceutical assessor for nicotine and CNS related products at the UK Medicines and Healthcare products Regulatory Agency (MHRA), he brings invaluable experience to the role.
Marshall will report to Rob Burton, Nerudia Head of Consultancy and Compliance. “We have created one of the largest teams of regulatory and scientific experts in nicotine-containing products in the world, which we will continue to strengthen by appointing top class experts,” said Burton. “We are therefore delighted that Paul has joined Nerudia and it’s a real coup for us to add such a seasoned regulator to our team.”
Marshall is an experienced regulatory scientist with a broad knowledge of regulatory strategy, Chemistry, Manufacturing and Controls, and drug development. In 11 years’ service at the MHRA he assessed over 400 Marketing Authorization (MA) applications and 1000 MA variations covering all dosage forms and regulatory submission routes. He has also been involved in over 40 formal scientific and regulatory advice meetings with companies developing products.
A registered UK pharmacist and Member of the Royal Pharmaceutical Society, Marshall contributed to the MHRA licensing procedure for e-cigarettes and other nicotine containing products. He is the chair of the British Standards Institute Electronic Cigarettes and E-liquids committee and member of European Committee for Standardization)TC/437 Working Group 4 on requirements and test methods for emissions from electronic cigarettes and e-liquids.